PEComas: Natural History and Prognostic Factors (PEComas)
National Multicenter Retrospective Study: PEComas: Natural History and Prognostic
Perivascular epithelioid cell tumors are rare and characterized by the expression of myomelanocytic markers. They belong to a complex tumor family that includes angiomyolipomas, lymphangioleiomyomatosis and other soft-tissue tumors. Given their rarity, the natural history of pecomas is not yet understood, and a comprehensive classification that integrates clinical, pathological and molecular features has not been achieved as of today.
This study is a national multicenter retrospective study to better understand the natural history of PEComas, excluding lymphangioleiomyomatosis and classic triphasic angiomyolipomas.
The primary purpose is the identification of prognostic markers impacting the relapse. Secondaries purposes are to identify prognostic markers impacting the overall survival and to have a better understanding of natural history
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Service d'Hématologie et d'Oncologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Major patient (≥18 years old)
- Minor patient (1 to 17 years old)
- PEComas diagnosed in France between 1990 and 2018 and read back by a pathologist referent of sarcomas
- Patient having agreed to the use of his medical data for the purpose of this research.
- Parental authorities having given their agreement for the reuse of their child's medical data for the purpose of this research.
Exclusion Criteria:
- Opposition of the patient (or his legal representative) to the reuse of his data for the purposes of this research
- Impossibility of giving the subject clear information
- Patient under safeguard of justice
- Patient under guardianship
- Lymphangioleiomyomatosis
- Classic triphasic angiomyolipoma
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Study of the prognostic factors associated with the risk of relapse
Time Frame: The period from January 1st, 1990 to December 31, 2018 will be examined
|
The period from January 1st, 1990 to December 31, 2018 will be examined
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7337
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.